Skip to main content

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2345${count})

  • Rapid Response Innovation Awards, 2009
    Crystal Structure of Alpha-Synuclein; Toward Rational Drug Design

    Objective/Rationale: The alpha-synuclein is implicated in the pathogenesis of Parkinson’s disease. An aggregated form of synuclein containing many molecules has been proposed to interact destructively...

  • Rapid Response Innovation Awards, 2009
    Probing the Neuroprotective Effects of Haploinsufficiency of RanBP2 in Neurotoxicant-induced Experimental Pre-clinical Models of Parkinson's Disease

    Objective/Rationale:
    A partial deficit in the level of Ran-binding protein-2 (RanBP2) confers neuroprotection to neurons upon aging and deleterious stimuli promoting oxidative stress, a stress...

  • Rapid Response Innovation Awards, 2009
    Identification of Substrates and Development of a Cell Based Assay for LRRK2

    Objective/Rationale:
    Inherited mutations in a gene called LRRK2 have recently been discovered to cause Parkinson’s disease. The LRRK2 gene encodes an enzyme called a kinase, which is more active when...

  • MJFF Research Grant, 2009
    PD Pre-clinical Model Repository

    Objective/Rationale:
    The Michael J. Fox Foundation (MJFF) is partnering with The Jackson Laboratory (JAX) to distribute pre-clinical models of Parkinson’s disease (PD). MJFF funding will allow JAX to...

  • Rapid Response Innovation Awards, 2009
    Phase I Trial of Phenylbutyrate to Prevent Progression of Parkinson's Disease

    Objective/Rationale:
    Parkinson’s disease gets worse over many years because dopamine neurons continue to die. Researchers have discovered a drug that prevents brain deterioration in pre-clinical...

  • Rapid Response Innovation Awards, 2009
    Aldehyde Dehydrogenase Activators as Novel Drugs For the Treatment of PD

    Objective/Rationale
    The accumulation of at least two toxic products in the brain called DOPAL and 4HNE results in death of neurons that are implicated in Parkinson’s Disease (PD). We identified a...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.